Mydecine Innovations Group Appoints Boustead Capital Markets LLP as Financial Advisor for its Planned Dual Listing on the London Stock Exchange

Mydecine Innovations Group, Inc, (CSE: MYCO) (OTC: MYCOF) (FSE: 0NFA) (“Mydecine” or the “Company”) announced the appointment of UK-based Boustead Capital Markets LLP (“Boustead”) to commence the dual listing process on the London Stock Exchange (“LSE” or the “Exchange”) for the admission of the Company’s common shares to the Standard Segment of the Official List’s Main Market.

Among the factors considered by the Company in pursuing the dual listing, Mydecine™ noted that the LSE currently has a limited number of sizable psychedelics-focused biotech companies. Mydecine, as a contributing member to Drug Science UK, the only completely independent, science-led drugs charity, believes the LSE listing will provide UK and European investors with greater, more local exposure to a new high-quality investment choice of a business type not currently available on the Exchange.

Highlights

Mydecine’s appointment of Boustead enables it to commence the LSE listing process and act on its intention for the Company’s common shares to trade on the Main Market in the next few months. In addition to its current listings in Canada, the United States, and Germany, the Company believes that a listing on the LSE makes it well-positioned to bring European investors into the Company’s share register.

The LSE listing is expected to provide all investors access and exposure to:

  • European Investor base in what the Company believes are Psychedelic-friendly countries such as the Netherlands, United Kingdom, Austria, and Portugal, to name a few
  • Support early and late-phase clinical trials
  • Expansion of the Company’s telehealth platform; Mindleap Health
  • Further development of extensive IP portfolio
  • Furthering the development of novel types of psilocybin-based medicine and unique formulations

Josh Bartch, CEO & Chairman of Mydecine Innovations Group, commented, “The Board of Directors has met a number of times deciding the best route and venue for the new listing of the Company’s securities, adding to our focus on shareholder value. We decided the LSE represented the best stock exchange for our investors, shareholders, and the ongoing growth of the Company. Additionally, it provides a great platform to measurably advance our investor reach within the European investor community. A LSE Listing offers a number of opportunities to fast-track further potential listings to exchanges such as NASDAQ or NYSE. Mydecine Innovations Group has a global reach through the Company’s various planned clinical trials, research facilities, partners and scientific advisors, some of which are located directly in the UK.”

Leave a Reply

Your email address will not be published. Required fields are marked *


About Us

The Green Market Report focuses on the financial news of the rapidly growing cannabis industry. Our target approach filters out the daily noise and does a deep dive into the financial, business and economic side of the cannabis industry. Our team is cultivating the industry’s critical news into one source and providing open source insights and data analysis


READ MORE



Recent Tweets

@GreenMarketRpt – 2 days

The Daily Hit: November 25, 2020

@GreenMarketRpt – 3 days

$PLNHF ⁦@Planet13lv⁩ Revenue Rises 36% To $22 Million, Turns A Profit

@GreenMarketRpt – 3 days

$VREOF ⁦@VireoHealth⁩ Revenue Rises 67%, Turns Profitable

Back to Top

You have Successfully Subscribed!